X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

For those who practice in the area of enforcement of pharmaceutical patents (i.e., patents directed to compounds, compositions or methods for treatment or prevention of disease, or maintenance of health), 2005 and the first eight months of 2006 are proving to be among the worst in memory. Why? Because in the last 20 months, the U.S. Court of Appeals for the Federal Circuit has completely or partially invalidated or held unenforceable nearly every pharmaceutical patent it has reviewed — more than two dozen in all, with only one upheld.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.